Medulloblastoma recurrence and metastatic spread are independent of colony-stimulating factor 1 receptor signaling and macrophage survival

[1]  M. Roussel,et al.  Small-molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastoma , 2021, Science Translational Medicine.

[2]  J. Westerga,et al.  Dynamic changes in glioma macrophage populations after radiotherapy reveal CSF-1R inhibition as a strategy to overcome resistance , 2020, Science Translational Medicine.

[3]  M. Roussel,et al.  Patient-derived orthotopic xenografts of pediatric brain tumors: a St. Jude resource , 2020, Acta Neuropathologica.

[4]  M. Goldsmith,et al.  Allosteric Inhibition of SHP2 Stimulates Antitumor Immunity by Transforming the Immunosuppressive Environment , 2020, Cancer Research.

[5]  C. Peer,et al.  Cerebrospinal fluid penetration of the colony-stimulating factor-1 receptor (CSF-1R) inhibitor, pexidartinib , 2020, Cancer Chemotherapy and Pharmacology.

[6]  Yi Chen,et al.  Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models , 2019, Journal of Experimental & Clinical Cancer Research.

[7]  T. MacDonald,et al.  Tumour-associated macrophages exhibit anti-tumoural properties in Sonic Hedgehog medulloblastoma , 2019, Nature Communications.

[8]  L. Coussens,et al.  Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors , 2019, Therapeutic advances in medical oncology.

[9]  S. Furlan,et al.  Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy , 2018, Neuro-oncology.

[10]  David T. W. Jones,et al.  A biobank of patient-derived pediatric brain tumor models , 2018, Nature Medicine.

[11]  R. Sposto,et al.  Colony stimulating factor 1 receptor blockade improves the efficacy of chemotherapy against human neuroblastoma in the absence of T lymphocytes , 2018, International journal of cancer.

[12]  David T. W. Jones,et al.  Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial , 2018, Cancer cell.

[13]  Yidan Ren,et al.  Advances in studies of tyrosine kinase inhibitors and their acquired resistance , 2018, Molecular Cancer.

[14]  R. Emerson,et al.  Immunophenotyping of pediatric brain tumors: correlating immune infiltrate with histology, mutational load, and survival and assessing clonal T cell response , 2018, Journal of Neuro-Oncology.

[15]  Kun Mu,et al.  Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma , 2017, Cancer cell.

[16]  J. Huse,et al.  Inhibition of colony stimulating factor-1 receptor abrogates microenvironment-mediated therapeutic resistance in gliomas , 2017, Oncogene.

[17]  Candice C. Poon,et al.  Glioblastoma-associated microglia and macrophages: targets for therapies to improve prognosis , 2017, Brain : a journal of neurology.

[18]  A. Najafi,et al.  Microglial repopulation resolves inflammation and promotes brain recovery after injury , 2017, Glia.

[19]  Alberto Mantovani,et al.  Tumour-associated macrophages as treatment targets in oncology , 2017, Nature Reviews Clinical Oncology.

[20]  G. Gustafsson,et al.  Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study , 2016, Journal of Neuro-Oncology.

[21]  J. Brown,et al.  Colony stimulating factor 1 receptor inhibition delays recurrence of glioblastoma after radiation by altering myeloid cell recruitment and polarization. , 2016, Neuro-oncology.

[22]  S. Leary,et al.  Survival After Relapse of Medulloblastoma , 2016, Journal of pediatric hematology/oncology.

[23]  T. Möller,et al.  Next generation transcriptomics and genomics elucidate biological complexity of microglia in health and disease , 2016, Glia.

[24]  Marzieh Vali,et al.  Tumor-Associated Macrophages in SHH Subgroup of Medulloblastomas , 2014, Clinical Cancer Research.

[25]  J. Blay,et al.  Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. , 2014, Cancer cell.

[26]  Brian L. West,et al.  Colony-Stimulating Factor 1 Receptor Signaling Is Necessary for Microglia Viability, Unmasking a Microglia Progenitor Cell in the Adult Brain , 2014, Neuron.

[27]  V. Amani,et al.  Characterization of Distinct Immunophenotypes across Pediatric Brain Tumor Types , 2013, The Journal of Immunology.

[28]  Christina S. Leslie,et al.  CSF-1R inhibition alters macrophage polarization and blocks glioma progression , 2013, Nature Medicine.

[29]  C. Chiang,et al.  Radiation Therapy-Induced Tumor Invasiveness Is Associated with SDF-1-Regulated Macrophage Mobilization and Vasculogenesis , 2013, PloS one.

[30]  Stephen Mok,et al.  CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. , 2013, Cancer research.

[31]  C. Lewis,et al.  Macrophage regulation of tumor responses to anticancer therapies. , 2013, Cancer cell.

[32]  R. Gascoyne,et al.  Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma. , 2012, Blood.

[33]  J. Segall,et al.  Microglial Stimulation of Glioblastoma Invasion Involves Epidermal Growth Factor Receptor (EGFR) and Colony Stimulating Factor 1 Receptor (CSF-1R) Signaling , 2012, Molecular medicine.

[34]  D. Hume,et al.  Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. , 2012, Blood.

[35]  J. Biegel,et al.  Novel cell lines established from pediatric brain tumors , 2012, Journal of Neuro-Oncology.

[36]  L. Fu,et al.  Mechanisms of acquired resistance to tyrosine kinase inhibitors , 2011 .

[37]  Hendrik Witt,et al.  Medulloblastoma comprises four distinct molecular variants. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  L. Esserman,et al.  Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome , 2011, Breast Cancer Research and Treatment.

[39]  Zhao-You Tang,et al.  High expression of macrophage colony-stimulating factor-1 receptor in peritumoral liver tissue is associated with poor outcome in hepatocellular carcinoma after curative resection. , 2010, The oncologist.

[40]  Jeffrey W. Pollard,et al.  Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.

[41]  H. Vogel,et al.  Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. , 2010, The Journal of clinical investigation.

[42]  Zhao-You Tang,et al.  High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  John Condeelis,et al.  Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis , 2006, Cell.

[44]  J. Parham,et al.  Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Yi-Chen Lin,et al.  Tumor-associated macrophages: the double-edged sword in cancer progression. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  J. Pollard,et al.  A Paracrine Loop between Tumor Cells and Macrophages Is Required for Tumor Cell Migration in Mammary Tumors , 2004, Cancer Research.

[47]  Helen Baines,et al.  Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice. , 2004, Cancer cell.

[48]  J. Krischer,et al.  Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  R J DUBOS,et al.  Health and disease. , 1960, JAMA.